Evidence map›Paper›PMID 31092203›Full record

ArticleBMC gastroenterology2019

Predictors of mortality in patients under treatment for chronic hepatitis B in Ethiopia: a prospective cohort study.

Hailemichael Desalegn, Hanna Aberra, Nega Berhe, Girmay Medhin, Bitsatab Mekasha, Svein Gunnar Gundersen, Asgeir Johannessen

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02344498 (Treatment of Hepatitis B in Resource-limited Settings - a Pilot Program in East Africa), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02344498 active not recruitingnot on this map

Treatment of Hepatitis B in Resource-limited Settings - a Pilot Program in East Africa

TypeobservationalSponsorOslo University HospitalRan2015 to 2026Enrolled7,350ConditionsHepatitis BArmsTenofovir disoproxil
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. [Correlation among age, sex, and liver diseases-related mortality risk in patients with hepatitis B virus-related liver cirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hailemichael DesalegnMedical Department, St. Paul's Hospital Millennium Medical College, Po. Box 1271, Addis Ababa, Ethiopia. hailed2003@yahoo.com.ORCID http://orcid.org/0000-0003-2042-5797
Hanna AberraMedical Department, St. Paul's Hospital Millennium Medical College, Po. Box 1271, Addis Ababa, Ethiopia.
Nega BerheAklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia.
Girmay MedhinAklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia.
Bitsatab MekashaMedical Department, St. Paul's Hospital Millennium Medical College, Po. Box 1271, Addis Ababa, Ethiopia.
Svein Gunnar GundersenResearch Unit, Sørlandet Hospital HF, Kristiansand, Norway.
Asgeir JohannessenCentre for Imported and Tropical Diseases, Oslo University Hospital, Ullevål, Oslo, Norway.

Funding

Norwegian Research Council 220622/H10South-Eastern Norway Regional Health Authority 2011068
6 · The paper itself

Abstract

backgroundAntiviral treatment for chronic hepatitis B (CHB) is largely unavailable in sub-Saharan Africa; hence, little is known about the prognosis after initiating treatment in African CHB patients. In this study we aimed to assess predictors of mortality in one of the largest CHB cohorts in sub-Saharan Africa.

methodsTwo-hundred-and-seventy-six CHB patients who started treatment with tenofovir disoproxil fumarate at a public hospital in Ethiopia between March 18, 2015, and August 1, 2017, were included in this analysis. Patients were followed up until October 1, 2017, and deaths were ascertained through hospital records and telephone interview with relatives. Decompensated cirrhosis was defined as current or past evidence of ascites, either by clinical examination or by ultrasonography. Cox proportional hazard models were used to identify independent predictors of mortality.

resultsThirty-five patients (12.7%) died during follow-up, 33 of whom had decompensated cirrhosis at recruitment. The median duration from start of treatment to death was 110 days (interquartile range 26-276). The estimated survival was 90.3, 88.2 and 86.3% at 6, 12 and 24 months of follow-up, respectively. Independent predictors of mortality were decompensated cirrhosis (adjusted hazard ratio [AHR] 23.68; 95% CI 3.23-173.48; p = 0.002), body mass index < 18.5 kg/m2 (AHR 3.65; 95% CI 1.73-7.72; p = 0.001) and older age (per 1-year increment; AHR 1.06; 95% CI 1.02-1.10; p = 0.007).

conclusionsDecompensated cirrhosis, low body mass index and older age were independent predictors of mortality. Improved access to antiviral treatment and earlier initiation of therapy could improve the survival of African CHB patients.

trial registrationNCT02344498 ( ClinicalTrials.gov identifier). Registered 16 January 2015.

Indexed as

AdolescentAdultAge FactorsAntiviral AgentsBody Mass IndexEthiopiaFemaleHepatitis B, ChronicHumansLiver CirrhosisMaleMiddle AgedProportional Hazards ModelsProspective StudiesRisk FactorsSurvival RateAntiviral AgentsTenofovirAntiviral therapyEpidemiologyHepatitis BResource-limited settingsSurvival

Identifiers

PMID31092203
PMCPMC6521482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.